Pharma-Bio Serv, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended April 30, 2023
June 14, 2023 at 04:31 pm EDT
Share
Pharma-Bio Serv, Inc. reported earnings results for the second quarter and six months ended April 30, 2023. For the second quarter, the company reported sales was USD 4.56 million compared to USD 4.97 million a year ago. Net income was USD 0.404654 million compared to USD 0.240027 million a year ago. Basic earnings per share from continuing operations was USD 0.018 compared to USD 0.01 a year ago. Diluted earnings per share from continuing operations was USD 0.018 compared to USD 0.01 a year ago.
For the six months, sales was USD 8.8 million compared to USD 9.99 million a year ago. Net income was USD 0.831086 million compared to USD 0.545271 million a year ago. Basic earnings per share from continuing operations was USD 0.036 compared to USD 0.024 a year ago. Diluted earnings per share from continuing operations was USD 0.036 compared to USD 0.024 a year ago.
Pharma-Bio Serv, Inc. is a compliance and technology transfer services consulting company. The Company operates through four segments: Puerto Rico technical compliance consulting, United States technical compliance consulting, Europe technical compliance consulting, and Puerto Rico microbiological and chemical laboratory testing division (Lab). The Company provides a range of compliance-related consulting services. The Company provides microbiological testing services and chemical testing services through its laboratory testing facility in Puerto Rico. The Company's technical consulting services include regulatory compliance, validation, technology transfer, engineering, project management and process support. The Company markets its services to pharmaceutical, chemical, biotechnology, medical devices, cosmetic and food industries, and allied products companies in Puerto Rico, the United States, Europe and Brazil.
PHARMA-BIO SERV, INC. 
